Howard Gurney
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Pulmonary and Respiratory Medicine top 0.5%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
Papers in
- Oncology 181
- Cancer Immunotherapy and Biomarkers 95
- Cancer Treatment and Pharmacology 23
-
- Renal cell carcinoma treatment 76
- Prostate Cancer Treatment and Research 66
- Co-authors
- Toni K. ChoueiriCora N. SternbergJoaquim BellmuntDaniel P. PetrylakRodolfo F. PeriniDavid I. QuinnAndrea NecchiRonald de Wit
- Journals
- Journal of Clinical Oncology (99 papers)Annals of Oncology (33 papers)British Journal of Cancer (9 papers)European Journal of Cancer (7 papers)European Urology (6 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Howard Gurney
273 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 5.9k
- Pulmonary and Respiratory Medicine 3.4k
- Cancer Research 1.4k
- Surgery 2.9k
- Hematology 650
Countries citing papers authored by Howard Gurney
This map shows the geographic impact of Howard Gurney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Gurney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Gurney more than expected).
Fields of papers citing papers by Howard Gurney
This network shows the impact of papers produced by Howard Gurney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Gurney. The network helps show where Howard Gurney may publish in the future.
Co-authors
The 25 scholars most cited alongside Howard Gurney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 3 | |
| 7 | 2024 | 7 | |
| 8 | 2024 | 3 | |
| 9 | 2024 | 6 | |
| 10 | Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up Hit paper breakdown → | 2023 | 118 |
| 11 | 2023 | 2 | |
| 12 | 2023 | 6 | |
| 13 | 2021 | 5 | |
| 14 | 2018 | 19 | |
| 15 | 2017 | 28 | |
| 16 | 2017 | 6 | |
| 17 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Hit paper breakdown → | 2017 | 2374 |
| 18 | 2017 | 5 | |
| 19 | 2016 | 64 | |
| 20 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer : Preliminary results | 1997 | 6 |
About Howard Gurney
Howard Gurney is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hematology and Surgery, having authored 286 papers that have together received 9.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (95 papers), Renal cell carcinoma treatment (76 papers), Prostate Cancer Treatment and Research (66 papers), Bladder and Urothelial Cancer Treatments (53 papers), Radiopharmaceutical Chemistry and Applications (30 papers), Cancer Genomics and Diagnostics (24 papers), Cancer Treatment and Pharmacology (23 papers) and Renal and related cancers (23 papers). The work is most often cited by research in Oncology (5.9k citations), Pulmonary and Respiratory Medicine (3.4k citations), Cancer Research (1.4k citations), Surgery (2.9k citations) and Hematology (650 citations). Howard Gurney has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Toni K. Choueiri, Cora N. Sternberg, Joaquim Bellmunt, Daniel P. Petrylak, Rodolfo F. Perini, David I. Quinn, Andrea Necchi, Ronald de Wit, David J. Vaughn and Yves Fradet. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.